European Union - English - EMA (European Medicines Agency)

sloan pharma s.a.r.l - botulinum toxin type b - torticollis - muscle relaxants - neurobloc is indicated for the treatment of cervical dystonia (torticollis).see section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type a.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

eagle pharma (m) sdn. bhd. - turpentine oil -

Canada - English - Health Canada

sloan jansan - chloroxylenol - lotion - 1.0% - chloroxylenol 1.0% - miscellaneous local anti-infectives

Canada - English - Health Canada

sloan jansan - chloroxylenol - lotion - 1.0% - chloroxylenol 1.0% - miscellaneous local anti-infectives

Canada - English - Health Canada

sloan jansan - chloroxylenol - liquid - 1.0% - chloroxylenol 1.0% - miscellaneous local anti-infectives

Canada - English - Health Canada

sloan jansan - chloroxylenol - liquid - 1.49% - chloroxylenol 1.49% - miscellaneous local anti-infectives

United States - English - NLM (National Library of Medicine)

us worldmeds, llc - tegaserod (unii: 458vc51857) (tegaserod - unii:458vc51857) - zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (ibs-c). limitations of use - the safety and effectiveness of zelnorm in men with ibs-c have not been established [see clinical studies (14)] . zelnorm is contraindicated in patients with: - a history of myocardial infarction (mi), stroke, transient ischemic attack (tia), or angina [see warnings and precautions (5.1)] - a history of ischemic colitis or other forms of intestinal ischemia [see warnings and precautions (5.2)] - severe renal impairment (egfr< 15 ml/min/1.73 m2 ) or end-stage renal disease [see use in specific populations (8.6)] - moderate and severe hepatic impairment (child-pugh b or c) [see use in specific populations (8.7)] - a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions [see adverse reactions (6.2)] - hypersensitivity to tegaserod [see adverse reactions (6.2)] risk summary availabl

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 5 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; crospovidone; hypromellose; lactose monohydrate; mannitol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 3 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; crospovidone; hypromellose; lactose monohydrate; mannitol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 2 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; crospovidone; hypromellose; lactose monohydrate; mannitol; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - afinitor is indicated for the: ? treatment of postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? treatment of progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? treatment of progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? treatment of advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? treatment of patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery. ? adjunctive treatment of patients aged 2 years and older with tsc and associated refractory seizures.